Investi Stratix
  • Politics
  • Economy
  • Forex
  • Stock
  • Editor’s Pick
  • Politics
  • Economy
  • Forex
  • Stock
  • Editor’s Pick
No Result
View All Result
Investi Stratix
No Result
View All Result

Catalent CEO to remain in charge of contract drugmaker after Novo Holdings’ buyout

by
October 21, 2024
in Economy
0
Catalent CEO to remain in charge of contract drugmaker after Novo Holdings’ buyout

(Reuters) – Catalent (NYSE:CTLT) CEO Alessandro Maselli said on Monday he will remain at the helm of the U.S.-based contract drugmaker after it is acquired by Novo Holdings, the controlling shareholder of weight-loss drug manufacturer Novo Nordisk (NYSE:NVO).

Maselli’s open letter comes on the back of criticism over Novo Holding’s $16.5-billion acquisition of Catalent, which U.S. consumer groups said last week could threaten competition in weight-loss drugs and cutting-edge gene therapies. The groups have asked the U.S. Federal Trade Commission to block the deal.

Catalent is a manufacturing partner of Danish company Novo for Wegovy, its popular and highly effective weight-loss drug from the GLP-1 class which some analysts predict could become a $150 billion market by 2030. It also makes Sarepta Therapeutics (NASDAQ:SRPT)’ gene therapy Elevidys and others.

In response to the criticism, CEO Maselli reiterated in a letter to the company’s customers that Catalent will continue to operate as an independent contract drugmaker.

“I want to be clear: our commitments to you will not change, your products will remain our focus and your proprietary information will be protected.”

Maselli has been Catalent’s CEO for over two years, and during his tenure the company conducted a strategic review as part of a settlement with activist investor Elliott Investment Management, which had been pushing for changes following manufacturing problems and declining revenue.

The deal with Novo Holding has secured approval from Brazil’s antitrust regulator, but is awaiting clearances in Europe and the United States.

Earlier this month, U.S. Senator Elizabeth Warren also asked the Federal Trade Commision to closely scrutinize the acquisition, and block the deal if the regulator finds it illegal.

Catalent said on Monday it would continue to offer fill and finish services for sterile products for large and small molecules, including gene and cell therapies.

This post appeared first on investing.com
Previous Post

Boeing shares rise after labor offer but analysts wary of worker pushback

Next Post

No, McDonald’s didn’t confirm Trump’s baseless claim about Kamala Harris

Next Post
No, McDonald’s didn’t confirm Trump’s baseless claim about Kamala Harris

No, McDonald’s didn’t confirm Trump’s baseless claim about Kamala Harris

Subscribe to InvestiStratix.com

    Popular News

    Sarepta shares fall 37% as FDA questions future of key gene therapy

    Sarepta shares fall 37% as FDA questions future of key gene therapy

    July 19, 2025
    Talen Energy surges 25% to ATH after strategic natural gas power plant acquisition

    Talen Energy surges 25% to ATH after strategic natural gas power plant acquisition

    July 19, 2025
    How billionaire Caltagirone could influence Italy’s banking M&A wave

    How billionaire Caltagirone could influence Italy’s banking M&A wave

    July 19, 2025
    Here’s why millions could be erased from UK’s debt pile

    Here’s why millions could be erased from UK’s debt pile

    July 18, 2025
    AWS layoffs hit hundreds as Amazon restructures amid AI push

    AWS layoffs hit hundreds as Amazon restructures amid AI push

    July 18, 2025

    Trending News

    Sarepta shares fall 37% as FDA questions future of key gene therapy

    Sarepta shares fall 37% as FDA questions future of key gene therapy

    July 19, 2025
    Talen Energy surges 25% to ATH after strategic natural gas power plant acquisition

    Talen Energy surges 25% to ATH after strategic natural gas power plant acquisition

    July 19, 2025

    Popular News

    • How billionaire Caltagirone could influence Italy’s banking M&A wave
      July 19, 2025
    • How billionaire Caltagirone could influence Italy’s banking M&A wave
      July 18, 2025

    About Us

    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Copyright © 2025 investistratix.com | All Rights Reserved

    No Result
    View All Result
    • Politics
    • Economy
    • Forex
    • Stock
    • Editor’s Pick

    Copyright © 2025 investistratix.com | All Rights Reserved